BioRestorative Therapies, Inc. Common Stock (NV) (BRTX) — Analysis Summary
BioRestorative Therapies, Inc. Common Stock (NV) (BRTX) has a market cap of $5.25M with year-over-year revenue growth of -10.3%. Net margin stands at -3959.4%. The stock trades at a P/E ratio of -0.5.
Key Takeaways
- Revenue changed -10.3% year-over-year
- Net margin of -3959.4%
- P/E ratio of -0.5
Compared to other companies in the SERVICES-MISC HEALTH & ALLIED SERVICES, NEC sector, BRTX posted revenue growth of -10.3% and trades at a P/E of -0.5.
BioRestorative Therapies, Inc. Common Stock (NV) (BRTX)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -3975.0% — severe operating losses
Net margin at -3089.6% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Gross margin at 92.1% — verify: very few businesses sustain >90% gross margin outside pure software/IP
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
Sector
SERVICES-MISC HEALTH & ALLIED SERVICES, NEC
Employees
14
Headquarters
MELVILLE, NY
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.